InscoBi Targets Global Hair Loss Market... "Obtains US Patent for Hair Loss Treatment"

[Asia Economy Reporter Yoo Hyun-seok] InscoBi announced on the 8th that it has obtained a U.S. patent for a ‘biological implant for hair growth promotion.’

Following the acquisition of patents in Korea and Japan, obtaining a patent in the United States?where more than 40% of the population experiences hair loss symptoms?is expected to accelerate the company’s entry into Western countries with high hair loss rates.

This patent involves hair loss treatment and improvement by implanting stem cells cultured under specific conditions into the body through a capsule for implantation, enhancing hair growth effects. It is characterized by the design that maximizes hair growth effects without other side effects by inserting stem cells into the capsule for implantation.

InscoBi is continuously conducting basic research based on the patents simultaneously acquired in Korea and Japan. Currently, based on the basic research results, the company is discussing plans for non-clinical studies with a CRO (Contract Research Organization) specializing in clinical trials.

Recently, as the hair loss population has expanded from men to women and from middle-aged to younger generations, the hair loss market is gaining attention as a high value-added industry. Hair loss occurs regardless of age due to various causes such as genetic factors, stress, and nutritional imbalance. Based on middle-aged men, the incidence rates of hair loss are 63% for Caucasians, 25% for African Americans, and 15% for Asians, leading to rapid growth in the hair loss care market in the U.S. and Europe.

A company official stated, “Globally, the hair loss population is continuously increasing, and recently, it has been identified that hair loss symptoms appear significantly about three months after COVID-19 sequelae, raising interest in hair loss treatment and improvement. The increase rate of patients diagnosed with hair loss over the past five years has reached approximately 24.8%, indicating growing demand for hair loss improvement and treatment.”

He added, “As interest in hair loss treatment grows, InscoBi expects that obtaining this U.S. patent will play a positive role in initiating non-clinical research. We plan to complete discussions with the CRO company and begin non-clinical studies within this year. Through the development of a hair growth program that supplements the shortcomings of existing hair loss treatments and enhances treatment effects, we will secure competitiveness in the global hair loss market.”

This content was produced with the assistance of AI translation services.